NCI-2023-00610

A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb�808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors

A Phase 1 study, which is the first of its kind in humans, is being conducted to find the appropriate dose and expand the investigation of XmAb®808 when used alongside Pembrolizumab, an immunotherapy medicine, in specific advanced solid tumors. The study aims to assess the safety, tolerance, how the body processes the drugs, and their effectiveness in treating these types of cancers.

Phase 1 study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

advanced: Advanced breast cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05585034

Clinical Trial Site: Columbia

To see all available clinical trials click here.